Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data

Main Article Content

Taofeek K Owonikoko
Kyriakos P Papadopoulos
Melissa L Johnson
Et al.

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi.

 

Copyright 2018 SKIN